Skip to main content
Captor Therapeutics S.A. logo

Captor Therapeutics S.A. — Investor Relations & Filings

Ticker · CTX ISIN · PLCPTRT00014 LEI · 259400JHH1S2I2S4O735 WAR Professional, scientific and technical activities
Open in API
Filings indexed 920 across all filing types
Latest filing 2026-03-02 Share Issue/Capital Cha…
Country PL Poland
Listing WAR CTX

About Captor Therapeutics S.A.

https://www.captortherapeutics.com/

Captor Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapeutics for diseases with high unmet medical needs. The company specializes in Targeted Protein Degradation (TPD), a technology that enables the elimination of disease-causing proteins previously considered "undruggable." Its core research and development activities are centered on creating new treatments for cancer and autoimmune diseases. To achieve this, Captor Therapeutics utilizes its proprietary Optigrade™ platform. This integrated drug discovery engine combines advanced technologies, including structural biology, proteomics, molecular modeling, and protein engineering, to identify and optimize novel drug candidates. The platform is designed to accelerate the development of degraders with superior therapeutic properties, aiming to provide new treatment options for severe conditions.

Recent filings

Filing Released Lang Actions
Zakończenie procesu budowania przyspieszonej księgi popytu w ramach oferty nowych akcji na okaziciela Serii Y oraz ustalenie ceny emisyjnej akcji Serii Y - Content (PL)
Share Issue/Capital Change Classification · 95% confidence The document describes a corporate action regarding the issuance of new shares (Series Y) following an accelerated book-building process. It details the final issue price and the decision to offer these shares to investors. This falls under the category of share issuance and capital changes, specifically related to the company's capital structure.
2026-03-02 Polish
załącznik
Share Issue/Capital Change Classification · 95% confidence The document is a detailed 'Subscription Rules' (Zasady Subskrypcji) document for a private placement/public offering of new series Y shares by Captor Therapeutics S.A. It outlines the legal basis (shareholder resolution), the target investor profile, the book-building process, allocation rules, and payment procedures for the new share issuance. This document is a formal offering document related to a capital increase and share issuance, which falls under the 'Share Issue/Capital Change' category.
2026-03-02 Polish
Rozpoczęcie procesu budowania przyspieszonej księgi popytu w ramach oferty nowych akcji na okaziciela serii Y, zawarcie umowy o plasowanie oferty akcji oraz zawarcie Umów Lock-Up przez Głównych Akc...
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory announcement from Captor Therapeutics S.A. regarding the initiation of an accelerated book-building process for a private subscription of new Series Y shares. It details the capital increase, the appointment of managers (IPOPEMA and mBank), and lock-up agreements for major shareholders. This falls under the category of announcements regarding new share issues and capital changes.
2026-03-02 Polish
Wykaz akcjonariuszy posiadających na Nadzwyczajnym Walnym Zgromadzeniu Spółki 2 marca 2026 r. co najmniej 5% głosów - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document provides a list of shareholders who held at least 5% of the votes at the Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie) held on March 2, 2026. This is a formal disclosure of voting results and shareholder participation at a general meeting, which falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2026-03-02 Polish
załącznik
Proxy Solicitation & Information Statement Classification · 95% confidence The document contains the official resolutions (Uchwała) passed during an Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie) of Captor Therapeutics S.A. It details the voting results, the agenda, and specific corporate actions approved, such as a capital increase via a private subscription of shares. This falls under the category of Proxy Solicitation & Information Statement (PSI) as it provides the materials and resolutions presented to shareholders for voting.
2026-03-02 Polish
Treść uchwał podjętych przez Nadzwyczajne Walne Zgromadzenie - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states that it is providing the content of resolutions adopted by the Extraordinary General Meeting (NWZ) held on March 2, 2026. It confirms that no objections were raised to the protocols. This is a formal notification of the results of a shareholder meeting, which falls under the category of Declaration of Voting Results.
2026-03-02 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.